Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Rhea-AI Summary

Clearmind Medicine (NASDAQ: CMND) said it is evaluating its lead candidate CMND-100 (MEAI) for potential FDA Breakthrough Therapy Designation based on positive results from its ongoing FDA‑approved Phase I/IIa Alcohol Use Disorder trial. The company has not yet submitted a BTD request and the FDA has not granted designation.

The announcement cites recent policy changes that may accelerate FDA review of certain psychedelic and neuroplastogen therapies.

Positive

• Positive clinical results reported in ongoing FDA‑approved Phase I/IIa trial
• Company is evaluating CMND‑100 for FDA Breakthrough Therapy Designation
• Focused on non‑hallucinogenic neuroplastogen candidate for Alcohol Use Disorder

Negative

• No Breakthrough Therapy Designation request submitted as of April 27, 2026
• FDA has not granted BTD for CMND‑100
• Trial is early‑stage (Phase I/IIa); data are preliminary

News Market Reaction – CMND

-10.09%

22 alerts

-10.09% Session close to close

+3.1% Peak Tracked

-17.6% Trough Tracked

$1.70M Market Cap

0.1x Rel. Volume

In the Apr 27 session, CMND declined 10.09%, reflecting a significant negative market reaction. Argus tracked a peak move of +3.1% during that session. Argus tracked a trough of -17.6% from its starting point during tracking. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -10.1% in the session following this news. A negative reaction despite the BTD-rel...

Analysis

The stock dropped -10.1% in the session following this news. A negative reaction despite the BTD-related communication fits a recent pattern where clearly positive CMND-100 updates sometimes preceded sharp declines. The company has multiple 6-K filings describing sizable convertible note financings, cash proceeds at a discount to principal, and note conversions into millions of shares, which may contribute to selling pressure. Investors monitoring this name often weigh clinical and regulatory milestones against the ongoing impact of structured financing activity.

Key Figures

Convertible note facility: $10,000,000 New notes principal: $2,700,000 Cash proceeds: $2,430,000 +5 more

8 metrics

Convertible note facility $10,000,000 Maximum aggregate principal under convertible note facility (6-K, Apr 20 & 14, 2026)

New notes principal $2,700,000 Aggregate principal of additional convertible promissory notes (6-K, Apr 20, 2026)

Cash proceeds $2,430,000 90% cash purchase price for $2.7M notes (6-K, Apr 20, 2026)

Converted principal $2,680,029.60 Principal converted into equity under notes (6-K, Apr 21, 2026)

Shares issued 4,466,716 shares Common shares issued on note conversion (6-K, Apr 21, 2026)

New notes principal $1,750,000 Principal of additional convertible notes (6-K, Apr 15 & 14, 2026)

Cash proceeds $1,575,000 90% cash purchase price for $1.75M notes (6-K, Apr 15 & 14, 2026)

Trial participants 18 participants Completed treatment and follow-up in Phase I/IIa CMND-100 AUD trial (6-K, Mar 30, 2026)

Historical Context

5 past events · Latest: Apr 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 20	Policy / EO response	Positive	-28.1%	Company highlighted Trump Executive Order and positioning of CMND-100 in policy.
Apr 20	Clinical topline data	Positive	+58.4%	CMND-100 met primary safety endpoint with favorable tolerability in AUD trial.
Apr 15	DSMB safety review	Positive	-28.6%	Independent DSMB recommended continuation after third cohort with no serious events.
Apr 14	Clinical endpoint met	Positive	-36.4%	Phase I/IIa trial met primary safety and tolerability endpoint for CMND-100.
Mar 30	Trial progress update	Positive	+22.7%	Reported completion of treatment and follow-up for 18 AUD trial participants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows mixed reactions: several clearly positive CMND-100 clinical updates saw sharp selloffs, while others produced strong rallies, yielding 3 divergences vs. 2 alignments.

Recent Company History

Over the past month, Clearmind has repeatedly updated progress for CMND-100 in its FDA-approved Phase I/IIa Alcohol Use Disorder trial. Milestones included meeting primary safety endpoints, a positive DSMB recommendation, and completion of treatment and follow-up for 18 participants. Market reactions have been volatile and inconsistent, with both large gains and steep drops on ostensibly positive news. Today’s evaluation of CMND-100 for potential FDA Breakthrough Therapy Designation fits into this ongoing clinical and regulatory narrative.

Key Terms

breakthrough therapy designation, fda, phase i/iia, alcohol use disorder, +2 more

6 terms

breakthrough therapy designation regulatory

"evaluating its lead candidate, CMND-100 (MEAI), for eligibility for the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy Designation (BTD)."

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

fda regulatory

"for eligibility for the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy Designation (BTD)."

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

phase i/iia medical

"ongoing FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder"

An early-stage clinical trial program that combines Phase I (primarily testing safety and finding a tolerable dose) with Phase IIa (initial checks for whether the drug shows signs of working in patients). Think of it as trying a new product with a small group to confirm it’s safe and gives early benefits before a larger rollout. For investors, these studies are major risk/reward checkpoints: positive results can boost value, while failures are common and costly.

alcohol use disorder medical

"Phase I/IIa clinical trial for Alcohol Use Disorder"

A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.

executive order regulatory

"recent Executive Order signed by President Trump, which accelerates FDA review processes"

An executive order is a formal directive issued by a country’s chief executive (for example, a president or prime minister) that tells government agencies how to apply or enforce laws and policies without waiting for new legislation. It matters to investors because these orders can quickly change rules, permits, taxes, trade or regulatory enforcement—like a manager changing company policy overnight—creating risks or opportunities that can affect company costs, revenues and share prices.

neuroplastogen medical

"non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems"

A neuroplastogen is a drug or compound designed to boost the brain’s ability to rewire and form new connections, enhancing recovery or adaptation after injury, stress, or disease. For investors, these molecules matter because they target underlying brain repair processes rather than just masking symptoms, offering the potential for durable benefits in conditions like depression, neurodegeneration, or cognitive decline—akin to giving a tired garden fresh tools to regrow and reshape itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Positive clinical results from Alcohol Use Disorder clinical trial may strengthen potential for eligibility for Breakthrough Therapy Designation

Vancouver, Canada, April 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it is evaluating its lead candidate, CMND-100 (MEAI), for eligibility for the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy Designation (BTD).

“We are encouraged by the recognition and positive developments in the space and are evaluating the suitability for potential Breakthrough Therapy Designation for CMND-100 based on the positive results demonstrated to date throughout our ongoing FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder,” said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine. “These data, combined with the recent Executive Order signed by President Trump, which accelerates FDA review processes for certain psychedelic and neuroplastogen therapies designated as breakthrough treatments, further support our belief that CMND-100 may meet the rigorous criteria for this important designation.”

The FDA’s Breakthrough Therapy Designation is granted to drugs intended to treat serious or life-threatening conditions where preliminary clinical evidence indicates the potential for substantial improvement over existing therapies on at least one clinically significant endpoints. Alcohol Use Disorder represents a life-threating with a significant unmet medical need, affecting millions worldwide with limited effective treatment options.

Clearmind Medicine remains committed to science-driven development and looks forward to continued engagement with the FDA as it advances CMND-100 toward providing safe, effective, and scalable non-hallucinogenic treatment options for patients.

As of the date hereof, the Company has not submitted a request for Breakthrough Therapy Designation for MEAI, and the FDA has not granted such designation.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its evaluation of the suitability for potential Breakthrough Therapy Designation for CMND-100, the timing and progress of its clinical trials, its belief that CMND-100 may meet the rigorous criteria for Breakthrough Therapy Designation, its commitment to science-driven development, and its continued engagement with the FDA as it advances CMND-100 toward providing safe, effective, and scalable non-hallucinogenic treatment options for patients. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What did Clearmind (CMND) announce about Breakthrough Therapy Designation for CMND‑100 on April 27, 2026?

Clearmind said it is evaluating CMND‑100 (MEAI) for potential FDA Breakthrough Therapy Designation. According to the company, this consideration is based on positive results reported to date from its ongoing FDA‑approved Phase I/IIa Alcohol Use Disorder trial and recent policy developments.

Has Clearmind (CMND) submitted a Breakthrough Therapy Designation request for CMND‑100?

No, Clearmind has not submitted a BTD request for CMND‑100 as of April 27, 2026. According to the company, the evaluation is ongoing and the FDA has not granted any Breakthrough Therapy Designation for MEAI to date.

What stage is the CMND‑100 (MEAI) clinical program for Alcohol Use Disorder?

CMND‑100 is being studied in an FDA‑approved Phase I/IIa clinical trial. According to the company, the trial has produced positive preliminary results, but it remains an early‑stage study and findings are described as preliminary.

What does potential FDA Breakthrough Therapy Designation mean for CMND‑100 and investors?

Breakthrough Therapy Designation could accelerate FDA review timelines for CMND‑100 if granted. According to the company, BTD would indicate preliminary evidence of substantial improvement over existing therapies on clinically significant endpoints.

Does the April 27, 2026 announcement mean the FDA has approved CMND‑100 for Alcohol Use Disorder?

No, the announcement does not indicate FDA approval of CMND‑100. According to the company, it is only evaluating eligibility for BTD and no submission or FDA designation has occurred as of the date provided.